All In Biotech

Drug Trial Radar · NCT03337698

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 314 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

314

Actual

Start

Dec 27, 2017

Primary completion

Oct 14, 2025

Study completion Nov 25, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • AtezolizumabDrug

    Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.

  • CobimetinibDrug

    Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.

  • RO6958688Drug

    Cycle 1: RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage. Subsequent cycles: RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.

  • DocetaxelDrug

    Docetaxel is administered by IV on Day 1 of each 21 day cycle.

  • CPI-444Drug

    CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.

  • PemetrexedDrug

    Pemetrexed is administered by IV on Day 1 of a 21 day cycle.

  • CarboplatinDrug

    Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.

  • GemcitabineDrug

    Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.

  • LinagliptinDrug

    Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.

  • TocilizumabDrug

    Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.

  • IpatasertibDrug

    Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.

  • BevacizumabDrug

    Bevacizumab is administered by IV on Day 1 of each 21-day cycle.

  • Sacituzumab GovitecanDrug

    Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.

  • RadiationOther

    Radiotherapy up to 21 days

  • EvolocumabDrug

    Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.

  • TiragolumabDrug

    Tiragolumab is administered on Day 1 of each 21 day cycle.

  • XL092Drug

    XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.

  • CamonsertibDrug

    Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Percentage of Participants With Objective Response (OR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)Time frame: Up to 50.4 months

Locations

29 sites in 7 countries. Site status is shown where the registry gives one.

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

    Las Vegas, Nevada

  • Columbia University Medical Center

    New York, New York

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Peter Mac Callum Cancer Center

    East Melbourne, Victoria, Australia

  • Centre Georges Francois Leclerc

    Dijon, France

  • Centre Léon Bérard

    Lyon, France

  • Hopital de la Timone

    Marseille, France

  • Institut Régional du Cancer de Montpellier

    Montpellier, France

  • Institut De Cancerologie De L'Ouest

    Saint-Herblain, France

  • Institut Universitaire du Cancer de Toulouse-Oncopole

    Toulouse, France

  • Rambam Medical Center

    Haifa, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)

    Songpa-gu, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Fundación Jimenez Díaz

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro-CIOCC

    Madrid, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Barts Cancer Institute

    London, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

  • Royal Marsden Hospital

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.